Overview

Anlotinib In Combination With PD-1/L1 Inhibitor As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study

Status:
Not yet recruiting
Trial end date:
2022-02-01
Target enrollment:
0
Participant gender:
All
Summary
Anlotinib In Combination With PD-1/L1 Inhibitor As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Xiaorong Dong
Criteria
Inclusion Criteria:

1. The subjects volunteered to join the study and signed the informed consent form. They
had good compliance and cooperated with the follow-up;

2. Patients between 18-75 years old;

3. Extensive small cell lung cancer confirmed by histopathology (according to Veterans
Administration lung study group, Valg stage) and did not progress after 4-6 cycles (21
days as a cycle) of first-line standard chemotherapy platinum combined with etoposide
[complete remission (CR), partial remission (PR) or stable (SD) according to recist1.1
standard];

4. The time interval between the first TRT and the end of the last chemotherapy should be
less than or equal to 6 weeks;

5. The life expectancy shall be at least 3 months;

6. ECoG score: 0-1

Exclusion Criteria:

1. Small cell lung cancer patients with other pathological types of tumor species;

2. Patients with pathological fracture in bone metastasis of small cell lung cancer;

3. Patients with central nervous system metastasis;

4. Patients who have received chest radiotherapy before;

5. Patients who have used vasotargeted drugs (such as bevacizumab, sunitinib, etc.)
including enrotinib and immunosuppressive agents before;

6. Imaging (CT or MRI) showed that the distance between the tumor focus and the large
blood vessel was less than or equal to 5 mm, or there was a central tumor invading the
local large blood vessel, or there was an obvious cavitary or necrotic tumor in the
lung;